was trending at about 39% market share in prurigo nodularis and about 8% in atopic dermatitis. The majority of patients starting treatment continue to be new to biologics. Galderma also continues to expand its healthcare professional engagement, supported by real world experience data to reinforce Nemluvio’s efficacy on skin clearance, complementing its position as the itch relief treatment of choice.

In International markets, which represent only a small portion of total Nemluvio sales, the launch trajectory remains even stronger. Meanwhile, Galderma is also advancing regulatory reviews in additional top markets.

Science-led innovation & medical education

Galderma reinforced its leadership in dermatology during the first quarter through impactful data presentations and industry-leading medical education at global congresses and company-led platforms.

At the 2026 American Academy of Dermatology (AAD) Annual Meeting, Galderma presented
=*=*=*=*=*=
当前为第9/27页
下一页-上一页-
=*=*=*=*=*=
返回新闻列表
返回网站首页